Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Perseus Proteomics Inc. has 1 pending office action in the Chemistry & Materials technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The portfolio's current activity is limited to this single pending matter, reflecting a concentrated prosecution strategy. This centralized approach means the company is currently interacting with only one technical division at the USPTO, which can lead to a more predictable prosecution environment if the examiner's style is well understood.
BERKELEY, EMILY R is the busiest examiner for this company, responsible for 1 pending office action. This single action constitutes the entire pending workload for the portfolio. The presence of only 1 distinct examiner and 1 distinct art unit indicates that the company's current patenting efforts are focused within a single specialized technical group. Practitioners should prioritize reviewing the past decisions of BERKELEY, EMILY R to effectively manage the prosecution of this single pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKELEY, EMILY R | 1 | 75.7% | +28.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030534 | METHOD FOR DETERMINING MEDICINAL EFFECT OR SENSITIVITY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY | BERKELEY, EMILY R | 97d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030534 | METHOD FOR DETERMINING MEDICINAL EFFECT OR SENSITIVITY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY | BERKELEY, EMILY R | 97d overdue |
| Art Unit | Apps |
|---|---|
| 1796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030534 | METHOD FOR DETERMINING MEDICINAL EFFECT OR SENSITIVITY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY | BERKELEY, EMILY R | 1796 | §101§103§112 | Final Rejection | 97d overdue | Pending | Apr 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial